UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 106

Sortiert nach

Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist

The Journal of pharmacology and experimental therapeutics, 1994-07, Vol.270 (1), p.228

1994

Link zum Volltext

Verfügbarkeit prüfen

Aspirin inhibits NF-kappaB and protects from angiotensin II-induced organ damage

The FASEB journal, 2001-08, Vol.15 (10), p.1822

2001

Link zum Volltext

Verfügbarkeit prüfen

Substituted piperidines - highly potent renin inhibitors due to induced fit adaptation of the active site

Bioorganic & medicinal chemistry letters, 1999-05, Vol.9 (10), p.1397-1402

1999

Link zum Volltext

Verfügbarkeit prüfen

Potent Vasoconstriction Mediated by Endothelin ETB Receptors in Canine Coronary Arteries

Circulation research, 1994-01, Vol.74 (1), p.105-114

1994

Link zum Volltext

Verfügbarkeit prüfen

Mineralocorticoid Receptor Affects AP-1 and Nuclear Factor-κB Activation in Angiotensin II–Induced Cardiac Injury

Hypertension (Dallas, Tex. 1979), 2001-02, Vol.37 (2, Part 2 Suppl), p.787-793

2001

Link zum Volltext

Verfügbarkeit prüfen

Downregulation of endothelin receptors by autocrine production of endothelin-1

American Journal of Physiology: Cell Physiology, 1993-07, Vol.265 (1), p.C188-C192

1993

Link zum Volltext

Verfügbarkeit prüfen

Endothelin antagonism with bosentan : a review of potential applications

Journal of molecular medicine (Berlin, Germany), 1999-04, Vol.77 (4), p.364-376

1999

Link zum Volltext

Verfügbarkeit prüfen

Functional effects of endothelin and regulation of endothelin receptors in isolated human nonfailing and failing myocardium

Circulation (New York, N.Y.), 1999-04, Vol.99 (14), p.1802-1809

1999

Link zum Volltext

Verfügbarkeit prüfen

Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use

The Journal of pharmacology and experimental therapeutics, 1999-08, Vol.290 (2), p.840

1999

Link zum Volltext

Verfügbarkeit prüfen

The pharmacology of bosentan

Expert opinion on investigational drugs, 1998-07, Vol.7 (7), p.1173-1192

1998

Link zum Volltext

Verfügbarkeit prüfen

Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist

Nature (London), 1993-10, Vol.365 (6448), p.759-761

1993

Link zum Volltext

Verfügbarkeit prüfen

Effect of Bosentan on NF-κB, Inflammation, and Tissue Factor in Angiotensin II–Induced End-Organ Damage

Hypertension (Dallas, Tex. 1979), 2000-08, Vol.36 (2), p.282-290

2000

Link zum Volltext

Verfügbarkeit prüfen

Hypertension-induced end-organ damage : A new transgenic approach to an old problem

Hypertension (Dallas, Tex. 1979), 1999, Vol.33 (1), p.212-218

1999

Link zum Volltext

Verfügbarkeit prüfen

Absence of ET(B)-mediated contraction in Piebald-lethal mice

Life sciences (1973), 1997, Vol.61 (3), p.255-263

1997

Link zum Volltext

Verfügbarkeit prüfen

Blood Pressure–Independent Effects in Rats With Human Renin and Angiotensinogen Genes

Hypertension (Dallas, Tex. 1979), 2000-02, Vol.35 (2), p.587-587

2000

Link zum Volltext

Verfügbarkeit prüfen

Piperidine renin inhibitors: from leads to drug candidates

Farmaco (Società chimica italiana : 1989), 2001-01, Vol.56 (1), p.21-27

2001

Link zum Volltext

Verfügbarkeit prüfen

Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm

The Journal of pharmacology and experimental therapeutics, 1997-12, Vol.283 (3), p.1110

1997

Link zum Volltext

Verfügbarkeit prüfen

The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo

Biochemical and biophysical research communications, 1992-07, Vol.186 (2), p.867-873

1992

Link zum Volltext

Verfügbarkeit prüfen

Angiotensin II (AT 1) Receptor Blockade Reduces Vascular Tissue Factor in Angiotensin II-Induced Cardiac Vasculopathy

The American journal of pathology, 2000-07, Vol.157 (1), p.111-122

2000

Link zum Volltext

Verfügbarkeit prüfen

In Vivo Pharmacology of Ro 46-2005, The First Synthetic Nonpeptide Endothelin Receptor Antagonist: Implications for Endothelin Physiology

Journal of cardiovascular pharmacology, 1993, Vol.22 Suppl 8 (Supplement 8), p.S377-S379

1993

Link zum Volltext

Verfügbarkeit prüfen

Cyclosporin A Protects Against Angiotensin II–Induced End-Organ Damage in Double Transgenic Rats Harboring Human Renin and Angiotensinogen Genes

Hypertension (Dallas, Tex. 1979), 2000-01, Vol.35 (1, Part 2 Suppl), p.360-360

2000

Link zum Volltext

Verfügbarkeit prüfen

Formation of 5-aminolevulinate via glutamate-1-semialdehyde and 4,5-dioxovalerate with participation of an RNA component in Scenedesmus obliquus mutant C-2A

Biochimica et biophysica acta, 1988-11, Vol.967 (2), p.135-140

1988

Link zum Volltext

Verfügbarkeit prüfen

Effect of different endothelin receptor antagonists and of the novel non-peptide antagonist Ro 46-2005 on endothelin levels in rat plasma

FEBS letters, 1993-10, Vol.333 (1), p.108-110

1993

Link zum Volltext

Verfügbarkeit prüfen

Up-Regulation of Endothelin-B Receptors in Atherosclerotic Human Coronary Arteries

Journal of cardiovascular pharmacology, 1996-01, Vol.27 (1), p.147-153

1996

Link zum Volltext

Verfügbarkeit prüfen

The role of ETB receptors in normotensive and hypertensive rats as revealed by the non‐peptide selective ETB receptor antagonist Ro 46‐8443

FEBS letters, 1996-03, Vol.383 (1-2), p.42-45

1996

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 106

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(96)
Mit Volltextzugriff
(99)

Publikationsform

Sprache

Englisch
(103)
Japanisch
(19)
Deutsch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(67)
Life Sciences & Biomedicine
(51)
Biological And Medical Sciences
(43)
Animals
(40)
Humans
(35)
Medical Sciences
(27)
Rats
(26)
Male
(22)
Endothelin
(21)
Endothelin Receptor Antagonists
(19)
Pharmacology. Drug Treatments
(18)
Pharmacology & Pharmacy
(17)
Fundamental And Applied Biological Sciences. Psychology
(16)
Cardiovascular System & Cardiology
(15)
Physical Sciences
(14)
Blood Pressure - Drug Effects
(12)
Cardiovascular System
(12)
Sulfonamides - Pharmacology
(12)
Chemistry
(11)
Biochemistry & Molecular Biology
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist

Aspirin inhibits NF-kappaB and protects from angiotensin II-induced organ damage

Substituted piperidines - highly potent renin inhibitors due to induced fit adaptation of the active site

Potent Vasoconstriction Mediated by Endothelin ETB Receptors in Canine Coronary Arteries

Mineralocorticoid Receptor Affects AP-1 and Nuclear Factor-κB Activation in Angiotensin II–Induced Cardiac Injury

Downregulation of endothelin receptors by autocrine production of endothelin-1

Endothelin antagonism with bosentan : a review of potential applications

Functional effects of endothelin and regulation of endothelin receptors in isolated human nonfailing and failing myocardium

Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use

The pharmacology of bosentan

Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist

Effect of Bosentan on NF-κB, Inflammation, and Tissue Factor in Angiotensin II–Induced End-Organ Damage

Hypertension-induced end-organ damage : A new transgenic approach to an old problem

Absence of ET(B)-mediated contraction in Piebald-lethal mice

Blood Pressure–Independent Effects in Rats With Human Renin and Angiotensinogen Genes

Piperidine renin inhibitors: from leads to drug candidates

Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm

The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo

Angiotensin II (AT 1) Receptor Blockade Reduces Vascular Tissue Factor in Angiotensin II-Induced Cardiac Vasculopathy

In Vivo Pharmacology of Ro 46-2005, The First Synthetic Nonpeptide Endothelin Receptor Antagonist: Implications for Endothelin Physiology

Cyclosporin A Protects Against Angiotensin II–Induced End-Organ Damage in Double Transgenic Rats Harboring Human Renin and Angiotensinogen Genes

Formation of 5-aminolevulinate via glutamate-1-semialdehyde and 4,5-dioxovalerate with participation of an RNA component in Scenedesmus obliquus mutant C-2A

Effect of different endothelin receptor antagonists and of the novel non-peptide antagonist Ro 46-2005 on endothelin levels in rat plasma

Up-Regulation of Endothelin-B Receptors in Atherosclerotic Human Coronary Arteries

The role of ETB receptors in normotensive and hypertensive rats as revealed by the non‐peptide selective ETB receptor antagonist Ro 46‐8443

Suchergebnisse filtern